Formosa pharmaceuticals announces development collaboration agreement with eyenovia

The collaboration will combine formosa's proprietary apnt™ nanoparticle formulation platform with eyenovia's optejet® dispensing technology for the development of new ophthalmic therapies in high-value indications with significant unmet medical needs. taipei , feb. 15, 2023 /prnewswire/ -- taiwan-based formosa pharmaceuticals ("formosa", 6838.two) announced today that the company has entered into a collaboration agreement with eyenovia, inc. ("eyenovia", nasdaq: eyen) for the development of novel ophthalmic therapeutics.
EYEN Ratings Summary
EYEN Quant Ranking